Become A Member

  1. Home
  2. April 2020
  3. 5. Examine the Efficacy of Rifaximin for Hepatic Encephalopathy Patients with Chronic Liver Disease
Article Image
Admin

5. Examine the Efficacy of Rifaximin for Hepatic Encephalopathy Patients with Chronic Liver Disease

Muhammad Uthman1, Syed Waseem Ahmad Mujtaba2 and Abdul Matin Qaisar3

 

ABSTRACT

 

Objective: To evaluate the effects and outcomes of rifaximin for the treatment of hepatic encephalopathy with chronic liver disease patients.

 

Study Design: Prospective/Randomized controlled trial study.

 

Place and Duration of Study: This study was conducted at the Department of Medicine, Shaikh Zayed Hospital Lahore from 1st July 2019 to 31st December 2019.

 

Materials and Methods: Eighty four patients of both genders whom were diagnosed with hepatic encephalopathy with chronic liver disease were including in this study. All the patients were divided into two groups, Group A included 42 patients and received treatment rifaximin with lactulose, Group B (control group) included 42 patients receiving placebo with lactulose. Follow-up was taken at 15 days or at discharge. Hepatic encephalopathy index and Child-Turcotte-Pugh (CTP) score and model for end-stage liver disease (MELD) were recorded to examine the outcome of treatment.

 

Results: In group A 30 patients were males and 12 were females while in Group B, 32 patients were males and 10 patients were females. In Group A, 34 patients were ages <60 years while 8 patients had ages >60 years, In Group B, 33 patients were ages <60 years and 9 patients were ages >60 years. At start of treatment Child-Turcotte-Pugh score p-value 0.467 and model for end-stage liver disease index p-value 0.874 were not statistically significant difference between two groups. Toward the finish of treatment there was noteworthy distinction discovered identified with hepatic encephalopathy file p-esteem 0.039 and model for end-stage liver ailment file p-esteem <0.05 than fake treatment gathering. Youngster Turcotte-Pugh score 0.621 was additionally lower in rifaximin bunch than Group B.

 

Conclusion: The use of rifaximin with lactulose for the treatment of hepatic encephalopathy resulted better outcome than placebo with respect to model for end-stage liver disease index and hospital stay. Key Word: Rifaximin, Chronic liver disease, Hepatic encephalopathy

 

Citation of article: Uthman M, Mujtaba SWA, Qaisar AM. Examine the Efficacy of Rifaximin for Hepatic Encephalopathy Patients with Chronic Liver Disease. Med Forum 2020;31(4):19-22